Kanwal Raghav, MBBS, MD

Dr Raghav on the Safety Profile of ABBV-400 Plus Chemo and Bevacizumab in Previously Treated mCRC

March 4th 2025

Kanwal P.S. Raghav, MBBS, MD, details the preliminary safety of a ABBV-400 regimen for the treatment of patients with previously treated mCRC.

Dr Raghav on ABBV-400 Plus 5-FU, Folinic Acid, and Bevacizumab in Previously Treated mCRC

January 31st 2025

Kanwal PS Raghav, MBBS, MD, discusses ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated mCRC.

Dr Raghav on the Rationale Behind DESTINY-CRC02 in HER2+ mCRC

June 23rd 2023

Kanwal P. S. Raghav, MBBS, MD, discusses the rationale behind the phase 2 DESTINY-CRC02 trial evaluating fam-trastuzumab deruxtecan-nxki in patients with metastatic colorectal cancer (mCRC) with HER2 amplification or overexpression.

Dr Raghav on Trastuzumab Deruxtecan in HER2+ mCRC

June 4th 2023

Kanwal P. S. Raghav, MBBS, MD, discusses primary findings from the phase 2 DESTINY-CRC02 trial (NCT04744831) of fam-trastuzumab deruxtecan-nxki (Enhertu) in patients with metastatic colorectal cancer with HER2 amplification or overexpression.

Dr. Raghav on Potential Combinations With Trastuzumab Deruxtecan in HER2+ CRC

January 28th 2022

Kanwal P.S. Raghav, MBBS, MD, discusses potential combinations with fam-trastuzumab deruxtecan-nxki in HER2-positive colorectal cancer.

Dr. Raghav on the Rationale for the DESTINY-CRC02 Trial in HER2+ mCRC

January 21st 2022

Kanwal P.S. Raghav, MBBS, MD, discusses the rationale for the ongoing phase 2 DESTINY-CRC02 trial in HER2-overexpressing metastatic colorectal cancer.

Dr. Raghav on Treatment Considerations in Metastatic CRC

December 8th 2021

Kanwal Raghav, MBBS, MD, discusses treatment considerations in metastatic colorectal cancer.

Dr. Raghav on Treatment Considerations With Regorafenib and TAS-102 in CRC

December 3rd 2021

Kanwal Raghav, MBBS, MD, discusses the safety profiles of regorafenib and trifluridine/tipiracil, and selecting between the agents for the treatment of patients with colorectal cancer.

Dr. Raghav on Regorafenib Dose Optimization in CRC

September 21st 2021

Kanwal Raghav, MBBS, MD, discusses optimal dosing strategies for regorafenib in patients with colorectal cancer.

Dr. Raghav on First-Line Treatment Options in CRC

September 7th 2021

Kanwal Raghav, MBBS, MD, discusses first-line treatment options for patients with colorectal cancer.

Dr. Raghav on Adjusting Dosing With Regorafenib in CRC

May 11th 2021

Kanwal Raghav, MBBS, MD, discusses adjusting dosing with regorafenib in patients with colorectal cancer.

Dr. Raghav on the Utility of Chemotherapy-Free Intervals in CRC

February 15th 2021

Kanwal Raghav, MBBS, MD, discusses the utility of chemotherapy-free intervals in colorectal cancer.

Dr. Raghav on Sequencing Therapies for Resectable Versus Unresectable CRC

January 26th 2021

Kanwal Raghav, MBBS, MD, discusses his approach to sequencing therapies for patients with resectable and unresectable colorectal cancer.

Dr. Raghav on the Role of Molecular Profiling in Treatment Selection in mCRC

January 18th 2021

Kanwal Raghav, MBBS, MD, discusses the role of molecular profiling in treatment selection for patients with metastatic colorectal cancer.

Dr. Raghav on the Utility of ctDNA in CRC

May 27th 2020

Kanwal Raghav, MBBS, MD, discusses the utility of circulating tumor DNA in colorectal cancer.

Dr. Raghav on Ongoing Research With Immunotherapy and Targeted Therapy in CRC

April 2nd 2020

Kanwal Raghav, MBBS, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy and targeted therapy in colorectal cancer (CRC).

Dr. Raghav on Treatment Options in Newly Diagnosed mCRC

March 25th 2020

Kanwal Raghav, MBBS, MD, discusses treatment options in newly diagnosed metastatic colorectal cancer.

Dr. Raghav on Activating the RAS/RAF/MEK/ERK Pathway in CRC

March 3rd 2020

Kanwal Raghav, MBBS, MD, discusses the activation of the RAS/RAF/MET/ERK pathway in colorectal cancer.

Dr. Kanwal Raghav on the Biology of HER2 Gene Amplification in mCRC

July 13th 2016

Dr. Raghav on HER2 Amplification in Patients With CRC

June 24th 2016

Kanwal Raghav, MBBS, MD, assistant professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study examining HER2 gene amplification in patients with metastatic colorectal cancer.